R&D from the Comfort of an Attic

May 17, 2011

Despite having seven employees who all work from home, FerroKin Biosciences plans to bring a drug to market in 2015, reports The Atlantic's Quinn Norton. This low overhead model, Norton adds, allows the companies to focus on nice drugs, and the one FerroKin is developing is to treat congenital anemias.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

An RNAi Approval

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Keep It Going

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Stop It There

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

This Week in PLOS

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Main menu